Marco is Partner at Forbion Capital Partners investing in Life Science companies. Before joining Forbion in 2007 Marco was Business Development Director at DSM Pharmaceutical Products, responsible for technology out-licensing and managing manufacturing projects. He started his professional career at vaccine company Cytos Biotechnology in Switzerland. After obtaining a Master’s degree in molecular biology from the University of Groningen in the Netherlands, Marco received his PhD in biotechnology from the ETH Institute for Technology in Zürich, Switzerland, and worked at the MRC Laboratory for Molecular Biology in Cambridge, UK. Apart from his Board role at RSPR Pharma he serves on the Board of Dezima Pharma and is Observer to the Boards of Exosome Diagnostics and Oxyrane.
Biotechnology